Substandard and Falsified Medicines Burden Model

While there is general awareness that substandard and falsified (SF) medicines make their way onto the market, countries do not have a way to quantify the impact of using these poor-quality medicines. This webinar will explore a new tool – the SF medicine burden model – that countries can use to estimate both the health and economic burden of using SF medicines. During the webinar, the USAID-funded Promoting the Quality of Medicines Plus (PQM+) program discusses the application of the model and results for two major MNCH products - Oxytocin and Amoxicillin dispersible tablet. The webinar introduces the model, describes how it was piloted with Oxytocin in Kenya, provides estimated results for SF Oxytocin and Amoxicillin in Africa and Asia, and describes how country-specific results for these countries can be readily calculated.